All in on early-stage, Qiming US bags $260M, recruits Atara founder Isaac Ciechanover for Fund III
Even as some of the public biotech companies in its portfolio bend under the weight of a bear market, Qiming Venture Partners USA is rolling up its sleeves to build more startups.
The VC firm has taken the wraps off a $260 million third fund, dubbed US Healthcare Fund III, to execute on the same strategy as previous funds: invest in early-stage therapeutics and healthcare technology companies in the US and the EU.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.